Benefits of ADHD Treatment In Rehabilitation (BATIR)

Benefits of in-prison OROS-methylphenidate vs. placebo treatment in detained people with attention-deficit/hyperactivity disorder: A randomized controlled trial

Research question

Stimulant drugs such as methylphenidate are first-line treatments for attention deficit hyperactivity disorder (ADHD). However, they are under-prescribed in prisons because of the risk of abuse, leading to a lack of adequate health care and social rehabilitation in this vulnerable population. The aim of this project is to compare the efficacy of methylphenidate treatment for ADHD with placebo, using a randomized clinical trial conducted in prison. Efficacy will be measured in terms of symptom severity, reduction of problems in prison, risk of recidivism, safety, adherence to treatment, retention in the study, cost-benefit, and recidivism. The project is likely to have important implications for reducing the vulnerability of people living in prison and promoting rehabilitation.


Project leader Prof. Stéphanie Baggio
Project team Dr. Leonel da Cunha Gonçalves
Mrs. Elena Poznyak
Mrs. Melina Romao dos Santos
Mrs. Nathalie Charmillot
Mrs. Isabelle Koscielniak
Partner(s) Prof. Joël Billieux , Institut de psychologie Faculté des Sciences Sociales et Politiques Université de Lausanne, Switzerland
Prof. Anja Dirkzwager , Netherlands Institute for the Study of Crime, Netherlands
Dr. Patrick Heller , Service de Médecine Pénitentiaire Hôpitaux Universitaires de Genève, Switzerland
Prof. Katia Iglesias , School of Health Sciences Fribourg, Switzerland
Dr. Karine Moschetti , Unisanté, University of Lausanne Centre for primary care and public health, Switzerland
Prof. Nader Perroud , Service des Spécialités Psychiatriques Département de Psychiatrie Hôpitaux Universitaires de Genève, Switzerland
Prof. Marie-Paule Schneider Voirol , Section des Sciences Pharmaceutiques Université de Genève, Switzerland
Prof. Nathalie Vernaz , Direction Générale de la Santé Pharmacie cantonale, Switzerland
Prof. Hans Wolff , Médecine et psychiatrie pénitentiaires Hôpitaux Universitaires de Genève, Switzerland
Funder(s) Swiss National Science Foundation
Study design Randomized controlled trial
Study start
October 2023
External links